CAPS Stock UPDATES Capstone Therapeutics Corp (CAPS) 0.2625 08/03/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Capstone Therapeutics Corp (CAPS) 0.2625 $CAPS

Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1b/2a Human Clinical Trial in Refractory Hypercholesterolemic Subjects
GlobeNewswire - Wed Jun 11, 11:47AM CDT
Capstone Therapeutics (OTCQB:CAPS) ("the Company" and its joint venture affiliate, LipimetiX Development, LLC ("JV" , announced today the initiation of dosing for the AEM-28 (Apo E mimetic peptide) Phase 1b/2a human clinical trial in refractory hypercholesterolemic subjects who are already on optimal cholesterol lowering therapy but are unable to reach target cholesterol levels.

Capstone Therapeutics Announces Operating Update Conference Call, Planned Initiation of AEM-28 Phase 1 Study and Fiscal Year 2013 Financial Results
GlobeNewswire - Thu Mar 27, 9:29AM CDT
Capstone Therapeutics (OTCQB:CAPS) ("the Company" and its joint venture affiliate, LipimetiX Development, LLC ("JV" , today will hold a conference call and webcast to provide an operating update, discuss the start of AEM-28 Phase 1 clinical studies and report financial results for the fiscal year 2013.

Capstone Therapeutics Announces Operating Update Conference Call
GlobeNewswire - Mon Mar 24, 1:30PM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company" , will hold a conference call and webcast on Thursday, March 27, 2014 at 4:30 pm EDT. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning March 27, 2014 at 7:30 pm EDT until midnight March 30, 2014, and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 12618657.

Health Briefs TV to Feature QAL Medical
PRWeb - Thu Jan 16, 12:01PM CST
The producers of Health Briefs TV are pleased to announce that QAL Medical will be featured in an upcoming segment on topics, trends, and issues related to "Improving Therapy Outcomes through Effective Technology Solutions" as part of the show's "Healthcare Today" series.

OTC Daily Alert Stock Watch - Capstone Therapeutics (OTCQB: CAPS)
WorldStockWire - Thu Aug 15, 9:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Capstone Therapeutics Will Provide an Operating Update and Announces Second Quarter 2013 Financial Results
GlobeNewswire - Wed Aug 14, 7:30AM CDT
Capstone Therapeutics (OTCQB:CAPS) (the "Company" , today will hold a conference call and webcast to provide an operating update and announced financial results for the second quarter 2013.

Capstone Therapeutics to Hold Quarterly Operating Update Conference Call
GlobeNewswire - Wed Aug 07, 1:16PM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company" , will hold a conference call and webcast on Wednesday, August 14, 2013 at 4:30 pm EDT. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning August 14, 2013 at 7:30 pm EDT until midnight August 17, 2013 and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 27383573.

Capstone Therapeutics Will Provide an Operating Update and Announces First Quarter 2013 Financial Results
GlobeNewswire - Wed May 15, 8:30AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company" , today will hold a conference call and webcast to provide an operating update and announced financial results for the first quarter 2013.

Capstone Therapeutics to Hold Operating Update Conference Call
GlobeNewswire - Wed May 08, 8:00AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company" , will hold a conference call and webcast on Wednesday, May 15, 2013 at 4:30 pm EDT. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning May 15, 2013 at 7:30 pm EDT until midnight May 18, 2013 and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 68894502.

Capstone Therapeutics Will Provide an Operating Update and Announces 2012 Financial Results
GlobeNewswire - Thu Mar 14, 7:15AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company" , today will hold a conference call and webcast to provide an operating update and 2012 financial results.

OTC Signal Daily Stock Watch - Capstone Therapeutics (CAPS)
WorldStockWire - Mon Dec 17, 10:45AM CST
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com



Scroll down for more posts ▼

Top 10 Most Recent News Articles

Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 0

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 141

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
Hyundai’s Third SUV Crown Matters Beyond the Trophy

Updated Category News Views 0

A Three-Year Streak Is Not Just Decorative Three straight SUV-brand wins can make even a cynical car watcher pause. Hyundai has been named U.S. News & World Report’s 2027 Best SUV Brand after editors assessed vehicles from 39 brands, and that is a useful bit of outside validation in a segment where nearly everybody is throwing sheet metal, screens, and marketing dollars...

Continue Reading
NextPatient’s KLAS Marks Signal Specialty Workflow Fit

Updated Category News Views 79

A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 131

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 151

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 30

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 90

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Dutch Solar Homes Face a 2027 Net Metering Reset Ahead

Updated Category News Views 24

A policy switch buried in a Dutch calendar is about to rearrange millions of kitchen-table energy calculations. On 1 January 2027, the Netherlands ends net metering, or salderingsregeling, and households with solar panels will no longer offset exported power against electricity bought from the grid. That is not some abstract regulatory footnote. It changes the value of...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 190

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading

Top 5 Most Recently Viewed Articles

DallasNews Shareholders Urged to Support Merger Deal with Hearst

Updated Category News Views 101

Overview of the DallasNews and Hearst Merger DallasNews Corporation, the parent company of The Dallas Morning News, has proposed a significant merger with Hearst, a prominent media organization. This merger offers an enticing cash value of $15.00 per share, bringing impressive benefits to shareholders. Recently, Glass Lewis, an independent proxy advisory firm, recommended...

Continue Reading
GitLab Director Karen Blasing's Recent Stock Transactions Explained

Updated Category News Views 154

Analyzing the Recent Insider Trading at GitLab GitLab Inc. (NASDAQ:GTLB) has recently drawn the attention of investors and market analysts due to stock transactions made by its director, Karen Blasing. A recent filing with the U.S. Securities and Exchange Commission revealed that Blasing sold a considerable amount of her stock holdings, totaling more than $173,000....

Continue Reading
Avenue Living's Strategic $350 Million Debenture Offering

Updated Category News Views 202

Avenue Living Announces $350 Million Senior Unsecured Debenture Offering Avenue Living (2014) LP has recently announced a significant financial move with a $350 million offering of Series B senior unsecured debentures. This opportunity is set to be priced at par and is due by September 25, 2028, indicating a long-term strategy for the company’s financing needs. Details...

Continue Reading
Fagron Reports Strong Financial Growth with Strategic Outlook

Updated Category News Views 349

Fagron's Remarkable Financial Performance Fagron, a global leader in pharmaceutical compounding, recently showcased its impressive results for the period ending December 31, 2024. The company’s financial achievements highlight significant growth across various sectors and regions in the pharmaceutical industry, reinforcing its commitment to excellence and innovation....

Continue Reading
Dizal's Sunvozertinib Receives Breakthrough Therapy Designation

Updated Category News Views 444

Dizal's Sunvozertinib Achieves Breakthrough Therapy Designation Dizal, a biopharmaceutical company dedicated to developing innovative cancer and immunological therapies, recently announced an important milestone. The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation for sunvozertinib, aimed at...

Continue Reading